Skip to main content
SpringerLink
Log in

New Approaches in Locoregional Therapies for Hepatocellular Carcinoma

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Hepatocellular carcinoma (HCC) represent actually the fifth most common cancer worldwide, with liver transplantation and hepatic resection who represent the standard of care of curative treatment. Unfortunately, not all patient could benefit of curative treatment. For such patients, locoregional or systemic therapies represent a valid option in order to achieve the best survival possible.

Methods

A review of most interesting paper actually present in literature on locoregional treatment for nonresectable nontransplantable HCC was performed.

Results

A detailed description on each different approach has been detailed in each chapter.

Conclusion

In case of nontransplantable and nonresectable HCC, locoregional treatment represent a valid alternative in management of this patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kluger MD, Memeo R, Laurent A, Tayar C, Cherqui D. Survey of adult liver transplantation techniques (SALT): an international study of current practices in deceased donor liver transplantation. HPB (Oxford). 2011;13(10):692–8.

    Article  Google Scholar 

  2. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40(6):1352–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15565564.

    Article  PubMed  Google Scholar 

  3. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52(2):762–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20564355.

    Article  CAS  PubMed  Google Scholar 

  4. Satmi A, Torzilli G. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Survival. 1991;69:925–9.

    Google Scholar 

  5. Kuang M, Xie XY, Huang C, Wang Y, Lin MX, Xu ZF, et al. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg. 2011;15(12):2165–71.

    Article  PubMed  Google Scholar 

  6. Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltinti G, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: Analysis of prognostic factors in 105 western patients. Cancer. 1995;76(10):1737–46.

    Article  CAS  PubMed  Google Scholar 

  7. Shi M, Guo R-P, Lin X-J, Zhang Y-Q, Chen M-S, Zhang C-Q, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245(1):36–43. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1867934&tool=pmcentrez&rendertype=abstract.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dufour JF, Greten TF, Raymond E, Roskams T, De T, Ducreux M, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22424438.

    Article  Google Scholar 

  9. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98(9):1210–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21766289.

    Article  CAS  PubMed  Google Scholar 

  10. Vitali GC, Laurent A, Terraz S, Majno P, Buchs NC, Rubbia-Brandt L, et al. Minimally invasive surgery versus percutaneous radio frequency ablation for the treatment of single small (≤3 cm) hepatocellular carcinoma: a case–control study. Surgical Endoscopy [Internet]. Springer US; 2015; Available from: http://link.springer.com/10.1007/s00464-015-4295-6

  11. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol. 2009;44 SUPPL 19:119–21.

    Article  PubMed  Google Scholar 

  12. Bruix J, Sherman M. AASLD PRACTICE GUIDELINE Management of hepatocellular carcinoma: an update. Hepatology. 2010;9(1)122–128.

  13. Scudamore CH, Lee SI, Patterson EJ, Buczkowski AK, July LV, Chung SW, et al. Radiofrequency ablation followed by resection of malignant liver tumors. Am J Surg. 1999;177(5):411–7.

  14. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22353262.

    Article  PubMed  Google Scholar 

  15. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56 Suppl 1:S75–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22300468.

    Article  PubMed  Google Scholar 

  16. Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One. 2014;9(1):e84484.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802. doi:10.1016/j.jhep.2012.05.007.

    Article  PubMed  Google Scholar 

  18. Lee SJ, Cho E, Kim R, Kim YH, Lim C, Kim SB. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg. 2015;19:98–102.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58(3):609–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23041304.

    Article  PubMed  Google Scholar 

  20. Poggi G, Tosoratti N, Montagna B, Picchi C. Microwave ablation of hepatocellular carcinoma. World J Hepatol. 2015;7(25):2578–89.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bertot LC, Sato M, Tateishi R, et al. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol. 2011;21:2584–96.

    Article  PubMed  Google Scholar 

  22. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:1.

    Article  Google Scholar 

  23. Ding J, Jing X, Liu J, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol. 2013;82:1379–84.

    Article  PubMed  Google Scholar 

  24. Salloum C, Subar D, Memeo D, Tayar C, Laurent A, Malek A, Azoulay D. Laparoscopic robotic liver surgery: the Henri Mondor initial experience of 20 cases. J Robot Surg. 2014;8(2):119–124.

  25. Coster HG. A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of “punch-through”. Biophys J. 1965;5:669–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Davalos RV, MirI L, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–31.

    Article  CAS  PubMed  Google Scholar 

  27. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6:37–48.

    Article  PubMed  Google Scholar 

  28. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat. 2005;4:699–705.

    Article  PubMed  Google Scholar 

  29. Thomson KR, Cheung W, EllisS J, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22:611–21.

    Article  PubMed  Google Scholar 

  30. Charpentier KP. Irreversible electroporation for the ablation of liver tumors: are we there yet? Arch Surg. 2012;147(11):1053–61.

    Article  PubMed  Google Scholar 

  31. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford). 2011;13(3):168–73.

    Article  Google Scholar 

  32. Kingham TP, Karkar AM, D’Angelica MI, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012;215:379–87.

    Article  PubMed  Google Scholar 

  33. Cannon R, Ellis S, Hayes D, Narayanan G, Martin 2nd RC. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–9.

    Article  PubMed  Google Scholar 

  34. Narayanan G. Irreversible electroporation. Semin Intervent Radiol. 2015;32(4):349–55.

    Article  PubMed  Google Scholar 

  35. Gonzalez-Beicos A, Venkat S, Songrug T, Poveda J, Garcia-Buitrago M, Poozhikunnath Mohan P, et al. Irreversible electroporation of hepatic and pancreatic malignancies: radiologic-pathologic correlation. Tech Vasc Interv Radiol. 2015;18(3):176–82.

    Article  PubMed  Google Scholar 

  36. Dollinger M, Beyer LP, Haimerl M, Niessen C, Jung EM, Zeman F, et al. Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience. Diagn Interv Radiol. 2015;21(6):471–5.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Silk MT, Wimmer T, LeeK S, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol. 2014;25:112–8.

    Article  PubMed  Google Scholar 

  38. Yamada R, Nakatsuka H, Nakamura K, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26:81–96.

    CAS  PubMed  Google Scholar 

  39. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med. 1995;332:1256–61

  40. Lo C-M, Ngan H, Tso W-K, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.

    Article  CAS  PubMed  Google Scholar 

  41. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  42. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  PubMed  Google Scholar 

  43. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.

    Article  CAS  PubMed  Google Scholar 

  44. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.

    Article  CAS  PubMed  Google Scholar 

  45. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.

    Article  CAS  PubMed  Google Scholar 

  46. Jung ES, Kim JH, Yoon EL, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013;58:1181–7.

    Article  PubMed  Google Scholar 

  47. Shim JH, Lee HC, Kim S-O, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708–18.

    Article  PubMed  Google Scholar 

  48. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55:1309–16.

    Article  PubMed  Google Scholar 

  49. Forner A, Gilabert M, Bruix J, Raoul J-L. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525–35.

    Article  CAS  PubMed  Google Scholar 

  50. Raoul J-L, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–20.

    Article  PubMed  Google Scholar 

  51. Hucke F, Sieghart W, Pinter M, et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;60:118–26.

    Article  PubMed  Google Scholar 

  52. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.

    Article  CAS  PubMed  Google Scholar 

  53. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  PubMed  Google Scholar 

  54. Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Bartenstein P, et al. Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization. J Nucl Med. 2015;56:333–8.

    Article  CAS  PubMed  Google Scholar 

  56. Iñarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D’Avola D, et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol. 2012;38:594–601.

    Article  PubMed  Google Scholar 

  57. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–8.

    Article  CAS  PubMed  Google Scholar 

  58. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58:2188–97.

    Article  CAS  PubMed  Google Scholar 

  59. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431–8.

    Article  PubMed  Google Scholar 

  60. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330–5.

    Article  PubMed  Google Scholar 

  61. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survival. Hepatology. 2010;52:1741–9.

    Article  CAS  PubMed  Google Scholar 

  62. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.

    Article  PubMed  Google Scholar 

  63. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  CAS  PubMed  Google Scholar 

  64. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, University Hospital of Strasbourg, IRCAD, Research Institute Against Cancer of the Digestive Tract, IHU-Strasbourg, Institute for Image-Guided Surgery, 1, place de l’Hôpital, 67091, Strasbourg, France

    Riccardo Memeo, Vito de Blasi, Zineb Cherkaoui, Ammar Dehlawi, Jacques Marescaux, Didier Mutter & Patrick Pessaux

  2. Inserm U1110, Institut de Recherche sur les Maladies Virale et Hepatiques, Strasbourg, France

    Riccardo Memeo & Patrick Pessaux

  3. Unit of Digestive, Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Henri Mondor Hospital, AP-HP, Université Paris Est-UPEC, 51, Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France

    Nicola de’ Angelis

  4. Service de Chirurgie Générale, Digestive et Endocrinienne, Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Université de Reims Champagne-Ardenne, Reims, France

    Tullio Piardi & Daniele Sommacale

Authors
  1. Riccardo Memeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vito de Blasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zineb Cherkaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ammar Dehlawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicola de’ Angelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tullio Piardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniele Sommacale
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jacques Marescaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Didier Mutter
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Patrick Pessaux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Riccardo Memeo.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interests.

Authors’ Contributions

All authors contributed to the writing of the paper. All authors have confirmed and approved the final version of this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Memeo, R., de Blasi, V., Cherkaoui, Z. et al. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. J Gastrointest Canc 47, 239–246 (2016). https://doi.org/10.1007/s12029-016-9840-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9840-6

Keywords

Search

Navigation